2019 Japanese Encephalitis R&D Pipeline Drugs, Companies, Trials and Developments

March 2019 | 40 pages | ID: 2C9F94EB800EN
VPAResearch

Abstracts

The global demand for Japanese Encephalitis treatment options is expected to report strong growth over the medium to long term future driven by consumption in major markets. Strong growth prospects of drugs for Japanese Encephalitis are driving leading companies to invest their resources on the pipeline.

Companies quickly advancing their drug candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Japanese Encephalitis pipeline companies from advancing their products.
Japanese Encephalitis Report Description
The H1-2019 pipeline review report on Japanese Encephalitis is a comprehensive study on drug candidates across different phases worldwide. This report evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date.
The Japanese Encephalitis pipeline guide presents information on all active drugs currently being developed for Japanese Encephalitis. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Japanese Encephalitis pipeline candidate are analyzed.

Further, current phase of development, mechanism of action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Japanese Encephalitis drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Japanese Encephalitis product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Japanese Encephalitis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed the report based on robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Japanese Encephalitis pipeline report includes-

• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise pipeline compounds
• Company wise list of pipeline compounds
• Mechanism of Action wise pipeline compounds
• For each pipeline product, the following details are provided-
• Snapshot (Drug, , Phase, Co Developer, Originator, Synonym, Orphan Drug Status, Type of Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Japanese Encephalitis pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Japanese Encephalitis pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into the market through in-depth strategic analysis review
• Know the list of companies participating in global Japanese Encephalitis pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

GLOBAL JAPANESE ENCEPHALITIS PIPELINE OVERVIEW

Key Findings, 2019
Disease Overview
Report Guide and Research Methodology

EXECUTIVE SUMMARY

Japanese Encephalitis Drugs under active development, H1@2019
Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
Companies involved in Japanese Encephalitis pipeline, H1@2019
Mechanism of Action wise Japanese Encephalitis Pipeline Candidates

ABIVAX SA JAPANESE ENCEPHALITIS PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

ENNAID THERAPEUTICS LLC JAPANESE ENCEPHALITIS PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

INDIAN IMMUNOLOGICALS LTD JAPANESE ENCEPHALITIS PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

KINETA INC JAPANESE ENCEPHALITIS PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

LIVZON PHARMACEUTICAL GROUP INC JAPANESE ENCEPHALITIS PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

SINOVAC BIOTECH LTD JAPANESE ENCEPHALITIS PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

VABIOTECH JAPANESE ENCEPHALITIS PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

LATEST JAPANESE ENCEPHALITIS DRUG PIPELINE DEVELOPMENTS, 2019

APPENDIX

About Us
Sources and Methodology
Contact Information